CLINICAL RESPONSE TO ROSUVASTATIN: CLINICAL EXOME PANEL (Sec. & CNVs) – 2 genes
Delivery time
3-4 weeks
Sample
Blood
This panel analyzes genetic variants that influence the efficacy and risk of muscle or liver toxicity associated with rosuvastatin treatment, one of the most widely used statins for cholesterol control and cardiovascular prevention. It evaluates polymorphisms in the ABCG2 and SLCO1B1 genes, which are involved in the transport and metabolism of rosuvastatin. Alterations in SLCO1B1 can reduce hepatic uptake of the drug, increasing its plasma concentration and the risk of myopathy or rhabdomyolysis, while variants in ABCG2 affect the drug's elimination and bioavailability, modifying the therapeutic response. The study allows for dose adjustments or the selection of alternative statins to optimize efficacy and minimize adverse effects.
Other tests
Exome panel analysis of 29 genes - idiopathic pulmonary fibrosis and surfactant protein deficiency
990,00€
511 gene analysis - epilepsy (using exome sequencing)
1.495,00€
Exome analysis of AGXT, GRHPR, and HOGA1 genes - primary hyperoxaluria
690,00€